In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on study results, an analyst ...

Atai Life Sciences N.V. reported positive top-line phase 2a results of BPL-003 in treating Alcohol Use Disorder patients.

Atai Life Sciences (NASDAQ:ATAI) reported positive topline results from a Phase 2a study of the psychedelic drug BPL-003 in the treatment of patients with moderate to severe alcohol use disorder, or ...

Life Sciences (ATAI) announced topline results from Beckley Psytech’s Phase 2a open-label study of BPL-003 in 12 patients with moderate to ...

H.C. Wainwright reiterated a Buy rating on shares of GH Research PLC (NASDAQ:GHRS), with a price target of $40.00. Currently ...

Coverage: Live radio commentary on Tennis Breakfast from 07:00 GMT on BBC 5 Sports Extra, plus live text commentaries on the BBC Sport website and app British number one Jack Draper dug deep into ...

He said: Get the latest updates on One Championship Rankings at Sportskeeda and more "We [my wife and I] received Ibogaine and 5-MeO-DMT as well in order to understand how each operation ...

GH Research biopharmaceutical company developing novel therapies for psychiatric and neurological disorders. The company has desigend its proprietary inhalable 5-MeO-DMT for depression. GH Research is ...

Usona, which aims to get psilocybin approved for depression by the Food and Drug Administration, is also studying 5-MeO-DMT, a psychoactive substance found in the venom of the Sonoran Desert toad, ...

Anecdotal evidence suggests that low, nonhallucinogenic doses of psychedelics can reduce symptoms of schizophrenia and psychosis. 5-Methoxy-N,N-dimethyltryptamine (5-MeO–DMT) has demonstrated ...